Does Rallies show 13F holders for TPST?

Yes. Rallies tracks hedge fund and 13F ownership data for TPST, including fund names, share counts, latest tracked quarter, and position changes when available.

Is TPST research on Rallies investment advice?

No. Rallies provides research, data, and educational context for TPST. It does not provide personalized investment advice.

TPST (Tempest Therapeutics, Inc. Common Stock) Stock Analysis - Hedge Fund Holdings

Tempest Therapeutics, Inc. Common Stock (TPST) is a publicly traded Healthcare sector company. As of May 21, 2026, TPST trades at $1.98 with a market cap of $26.95M and a P/E ratio of -0.29. TPST moved +5.62% today. Year to date, TPST is +31.91%; over the trailing twelve months it is -44.48%. Its 52-week range spans $1.20 to $10.34. Analyst consensus is buy with an average price target of $11.00. Rallies surfaces TPST's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns TPST stock?

Hedge funds tracked by Rallies that own TPST include Citadel Advisors and Two Sigma. The latest tracked quarter is Dec 31, 2024. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Tempest Therapeutics, Inc. Common Stock.

TPST Key Metrics

Key financial metrics for TPST
Metric	Value
Price	$1.98
Market Cap	$26.95M
P/E Ratio	-0.29
EPS	$-6.33
Dividend Yield	0.00%
52-Week High	$10.34
52-Week Low	$1.20
Volume	330
Avg Volume	0
Revenue (TTM)	$0
Net Income	$-26.26M
Gross Margin	0.00%

Top Hedge Funds Holding TPST

Citadel Advisors holds 64.00K shares of TPST, changed +17.22% as of Dec 31, 2024.
Two Sigma holds 22.92K shares of TPST, changed -77.13% as of Sep 30, 2024.

Latest TPST News

Tempest Achieves 100% CR in TPST-2003 Trials and Secures AGCTC Manufacturing Partner — May 14, 2026
Tempest’s TPST-2003 Yields 100% CR in 15 Patients, 23.1-Month PFS — May 6, 2026
Tempest to Detail 100% CR in Six rrMM Patients at ISCT — Apr 29, 2026
Tempest Therapeutics Secures Lentiviral Vector, Readies TPST-2003 for Q4 2026 Registrational Study — Apr 22, 2026
Tempest Therapeutics Posts $26.3M Net Loss, Reports 100% CR in TPST-2003 Trial — Mar 30, 2026

Recent TPST Insider Trades

Angel Matthew bought 231.48K (~$500.00K) on Mar 24, 2026.
Versant Venture Capital VI, L.P. sold 388.00K (~$426.99K) on Aug 12, 2024.
Versant Venture Capital VI, L.P. sold 400.00K (~$540.04K) on Aug 8, 2024.

TPST Analyst Consensus

1 analysts cover TPST: 0 strong buy, 1 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $11.00.

Common questions about TPST

Who owns TPST stock?: Hedge funds tracked by Rallies that own TPST include Citadel Advisors and Two Sigma. The latest tracked quarter is Dec 31, 2024. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Tempest Therapeutics, Inc. Common Stock.
Does Rallies show 13F holders for TPST?: Yes. Rallies tracks hedge fund and 13F ownership data for TPST, including fund names, share counts, latest tracked quarter, and position changes when available.
Is TPST research on Rallies investment advice?: No. Rallies provides research, data, and educational context for TPST. It does not provide personalized investment advice.